Subclinical Toxicity Detection

Subclinical toxicity detection identifies organ damage preceding clinical symptoms enabling early intervention. Biomarker elevation indicates tissue injury before symptoms. Imaging surveillance reveals structural changes. Biopsies demonstrate histological damage. Early detection permits dose reduction preventing progression.

Clinical monitoring employs sensitive biomarkers. Preventive dose modification reduces severe toxicity. Regulatory submissions address subclinical monitoring. Post-approval surveillance detects subclinical patterns. Emerging technologies improve detection sensitivity.